MM
Haematology · 2006–2026
70decisions
16medicines
42carried consumer input
2,306individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| teclistamab Treatment of adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least 3 prior lines of therapy, including a proteasome… | Mar 2026 | Recommended with restriction | no section in document |
| daratumumab Treatment of transplant ineligible, newly diagnosed multiple myeloma in combination with lenalidomide and dexamethasone. | Mar 2025 | Recommended with restriction | 244 individuals |
| elranatamab Treatment of patients with relapsed or refractory multiple myeloma who have received at least 3 prior lines of therapy, including a proteasome inhibitor, an… | Dec 2025 | 177 individuals | |
| belantamab mafodotin Relapsed and/or refractory multiple myeloma (RRMM) after one prior line of therapy, in combination with bortezomib and dexamethasone. | Nov 2025 | Not recommended | unclear |
| elranatamab Treatment of adult patients with relapsed or refractory multiple myeloma who have received at least 3 prior therapies, including a proteasome inhibitor, an… | Jul 2024 | Not recommended | 14 individuals Myeloma Australia · Leukaemia Foundation · Rare Cancers Australia |
| pomalidomide Treatment of multiple myeloma in patients requiring dose adjustments due to haematological toxicities. The submission was for the addition of 1 mg and 2 mg… | Jul 2023 | Recommended | input received Rare Cancers Australia |
| daratumumab Treatment of transplant ineligible, newly diagnosed multiple myeloma in combination with lenalidomide and dexamethasone. | Mar 2023 | Not recommended | 100 individuals Myeloma Australia · Haematology Society |
| lenalidomide Treatment of newly diagnosed multiple myeloma (as monotherapy, doublet therapy, or triplet therapy), progressive multiple myeloma, relapsed/refractory multiple… | Nov 2023 | Recommended | input received Rare Cancers Australia |
| bortezomib Multiple myeloma. The submission requests listing of two new forms of bortezomib solution for injection (2.5 mg/mL and 3.5 mg/1.4 mL) under the same… | Mar 2022 | Recommended with restriction | 9 individuals |
| bortezomib Multiple myeloma. Listing of two new solution for injection forms (2.5 mg/mL and 3.5 mg/1.4 mL) under the Section 100 Efficient Funding of Chemotherapy Program. | Mar 2022 | Recommended with restriction | 9 individuals |
| carfilzomib Treatment of relapsed or refractory multiple myeloma (RRMM) after at least one prior therapy, in combination with lenalidomide and dexamethasone. | Mar 2022 | Recommended | 12 individuals Myeloma Australia · Leukemia Foundation |
| ixazomib Relapsed and/or refractory multiple myeloma (RRMM) after at least two prior therapies, in combination with lenalidomide and dexamethasone. | Mar 2022 | Not recommended | 10 individuals Myeloma Australia · Leukemia Foundation |
| selinexor Treatment of adult patients with relapsed and/or refractory multiple myeloma (RRMM) who have received at least four prior therapies and whose disease is… | Mar 2022 | Recommended with restriction | 6 individuals Myeloma Australia |
| selinexor Treatment of adult patients with relapsed and/or refractory multiple myeloma (RRMM) who have received at least one prior therapy, in combination with… | Mar 2022 | Not recommended | 11 individuals Myeloma Australia · Leukaemia Foundation · Leukemia Foundation |
| selinexor Relapsed and/or refractory multiple myeloma (RRMM) in adult patients who have received at least one prior therapy, in combination with bortezomib and… | Nov 2022 | Recommended | 64 individuals |
| bortezomib Treatment of multiple myeloma as a new 2.5 mg vial size under the Efficient Funding of Chemotherapy program, with the same indications as existing bortezomib… | Jul 2021 | Recommended with restriction | 10 individuals |
| bortezomib Multiple myeloma, including previously untreated disease (in combination with melphalan and prednisone, or as induction therapy prior to high-dose… | Jul 2021 | Recommended with restriction | 11 individuals |
| daratumumab Relapsed or refractory multiple myeloma as second-line treatment in combination with bortezomib and dexamethasone. | Jul 2021 | Recommended with restriction | 38 individuals Myeloma Australia · Leukaemia Foundation |
| elotuzumab Treatment of relapsed or refractory multiple myeloma (RRMM) in combination with lenalidomide and dexamethasone, in patients who have received at least one… | Jul 2021 | Recommended with restriction | 20 individuals |
| selinexor Treatment of relapsed and/or refractory multiple myeloma in combination with bortezomib and dexamethasone for adult patients who have received at least one… | Jul 2021 | Not recommended | 18 individuals Myeloma Australia · Rare Cancers Australia · Leukaemia Foundation |
| selinexor Treatment of adult patients with relapsed and/or refractory multiple myeloma (RRMM) who have received at least four prior therapies and whose disease is… | Jul 2021 | Not recommended | 3 individuals Myeloma Australia · Rare Cancers Australia · Leukaemia Foundation |
| carfilzomib Relapsed or refractory multiple myeloma (RRMM) in combination with dexamethasone (Cd), with addition of a 70 mg/m² once weekly dosing regimen to the existing… | Jul 2020 | Recommended with restriction | 37 individuals |
| daratumumab Relapsed and/or refractory multiple myeloma as second-line therapy in combination with bortezomib and dexamethasone. | Jul 2020 | Recommended with restriction | 99 individuals |
| plitidepsin Treatment of relapsed/refractory multiple myeloma in patients refractory to a proteasome inhibitor and an immunomodulatory drug (third-line setting) or in… | Mar 2020 | Not recommended | 49 individuals Myeloma Australia · Leukaemia Foundation · South East Myeloma Support Group · Rare Cancers Australia · National Institute |
| elotuzumab Treatment of relapsed or refractory multiple myeloma (RRMM) in combination with lenalidomide and dexamethasone in patients with progressive disease after at… | Nov 2020 | Not recommended | input received Myeloma Australia · Scientific Group · Leukaemia Foundation · Rare Cancers Australia |
| ixazomib Relapsed and/or refractory multiple myeloma (RRMM) in patients who have experienced disease progression with at least one prior therapy, in combination with… | Nov 2020 | Not recommended | 38 individuals Myeloma Australia · Scientific Group · Leukaemia Foundation · Rare Cancers Australia |
| lenalidomide Treatment of newly diagnosed multiple myeloma (NDMM) in combination with bortezomib and dexamethasone for patients ineligible for autologous stem cell… | Aug 2019 | Recommended with restriction | 27 individuals |
| denosumab Treatment of patients with multiple myeloma who have renal impairment (creatinine clearance ≤ 60 mL/min), to prevent skeletal related events. | Jul 2019 | Not recommended | 25 individuals |
| lenalidomide Maintenance treatment in patients with newly diagnosed multiple myeloma (NDMM) who have undergone an autologous stem cell transplant (ASCT). | Jul 2019 | Recommended with restriction | 75 individuals |
| plitidepsin Treatment of relapsed/refractory multiple myeloma (RRMM) in patients who are refractory to a proteasome inhibitor and an immunomodulatory drug (third-line) or… | Jul 2019 | Not recommended | 32 individuals |
| pomalidomide Treatment of relapsed or refractory multiple myeloma (RRMM) in patients who have undergone or are ineligible for stem cell transplant and have received at… | Jul 2019 | Not recommended | 33 individuals |
| daratumumab Relapsed or refractory multiple myeloma (RRMM) in combination with bortezomib and dexamethasone for patients with progressive disease after at least one prior… | Mar 2019 | Recommended with restriction | input received |
| lenalidomide Maintenance treatment in patients with newly diagnosed multiple myeloma (NDMM) who have undergone autologous stem cell transplant (ASCT). | Mar 2019 | Recommended with restriction | 107 individuals |
| lenalidomide Amendment of restriction level for existing PBS listings for newly diagnosed multiple myeloma (ND MM) ineligible for stem cell transplant and relapsed or… | Mar 2019 | Not recommended | 51 individuals |
| daratumumab Relapsed or refractory multiple myeloma (RRMM) in patients who have received one prior therapy (second-line treatment), in combination with bortezomib and… | Nov 2019 | Deferred | 89 individuals |
| pomalidomide Treatment of relapsed or refractory multiple myeloma (RRMM) in patients who have undergone or are ineligible for stem cell transplant and have received one… | Nov 2019 | Recommended with restriction | 52 individuals |
| denosumab Treatment of patients with bone lesions due to multiple myeloma for the prevention of skeletal-related events. | Jul 2018 | Not recommended | 96 individuals |
| zoledronic acid Multiple myeloma; bone metastases due to breast cancer or castration-resistant prostate cancer; hypercalcaemia of malignancy. | Jul 2018 | Recommended with restriction | no section in document |
| carfilzomib Treatment of patients with multiple myeloma who have failed at least one prior line of treatment, used in combination with dexamethasone. | Mar 2018 | Recommended with restriction | none received |
| lenalidomide Maintenance therapy in patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplant (ASCT). | Mar 2018 | Recommended with restriction | 199 individuals |
| carfilzomib Amendment to pomalidomide restriction to allow use of any proteasome inhibitor (bortezomib or carfilzomib) prior to treatment with pomalidomide in multiple… | Nov 2018 | Not recommended | none received |
| denosumab Prevention of skeletal related events in patients with multiple myeloma. | Nov 2018 | Not recommended | none received |
| carfilzomib Treatment of relapsed or refractory multiple myeloma (RRMM) in patients with progressive disease after at least one prior therapy, in combination with… | Jul 2017 | Recommended with restriction | 75 individuals Myeloma Australia |
| pomalidomide Treatment of patients with relapsed and refractory multiple myeloma who have experienced severe intolerance or toxicity to lenalidomide and/or bortezomib. | Mar 2017 | Not recommended | input received |
| daratumumab Treatment of relapsed or refractory multiple myeloma (RRMM) in combination with bortezomib and dexamethasone or lenalidomide and dexamethasone in patients with… | Nov 2017 | Not recommended | 123 individuals |
| lenalidomide Extension of listing to remove the requirement for thalidomide trial prior to lenalidomide use, and to allow retreatment with lenalidomide in relapse or… | Nov 2017 | Recommended | no section in document |
| pomalidomide Treatment of patients with relapsed and refractory multiple myeloma who have experienced severe intolerance or toxicity to lenalidomide and/or bortezomib. | Nov 2017 | Recommended | none received |
| bortezomib Treatment of multiple myeloma in newly diagnosed patients (ineligible for and eligible for high-dose chemotherapy with autologous stem cell transplantation)… | Mar 2016 | Recommended with restriction | none received |
| lenalidomide First-line therapy in the treatment of patients with newly diagnosed symptomatic multiple myeloma (NDMM) who are ineligible for stem cell transplant. | Mar 2016 | Recommended with restriction | no section in document |
| pomalidomide Treatment of patients with relapsed and refractory multiple myeloma who have received at least two prior treatment regimens, including both lenalidomide and… | Mar 2016 | Not recommended | none received |
| carfilzomib Treatment of relapsed or refractory multiple myeloma in patients who have received at least one prior therapy, using either carfilzomib with dexamethasone (Cd)… | Nov 2016 | Not recommended | 168 individuals |
| lenalidomide Treatment of patients with newly diagnosed symptomatic multiple myeloma who are ineligible for stem cell transplant, given in combination with dexamethasone. | Nov 2015 | Deferred | input received |
| pomalidomide Treatment of patients with relapsed and refractory multiple myeloma who have received at least two prior treatment regimens, including both lenalidomide and… | Jul 2014 | Not recommended | 175 individuals |
| pomalidomide Treatment in combination with dexamethasone of patients with relapsed and/or refractory multiple myeloma who have received and failed prior treatment with both… | Nov 2014 | Recommended with restriction | none received |
| bortezomib treatment in combination with chemotherapy, of a patient with newly diagnosed symptomatic multiple myeloma who is eligible for high dose chemotherapy and a… | Mar 2012 | Recommended | no section in document |
| bortezomib Induction therapy in newly diagnosed symptomatic multiple myeloma patients eligible for high dose chemotherapy and autologous stem cell transplant, as part of… | Mar 2012 | Recommended | no section in document |
| bortezomib Initial and continuing PBS-subsidised treatment, in combination with a corticosteroid or in combination with a corticosteroid and melphalan or… | Jul 2011 | Recommended with restriction | unclear |
| bortezomib First-line treatment of multiple myeloma in patients newly diagnosed who have severe renal failure or in patients treated with thalidomide who have a resultant… | Mar 2011 | Recommended | unclear |
| bortezomib First-line treatment of newly diagnosed multiple myeloma in patients not eligible for high-dose chemotherapy, in combination with melphalan or cyclophosphamide… | Mar 2010 | Recommended with restriction | no section in document |
| bortezomib First-line treatment of newly diagnosed multiple myeloma in patients not eligible for high-dose chemotherapy, in combination with melphalan or cyclophosphamide… | Mar 2010 | Recommended with restriction | no section in document |
| bortezomib Treatment of previously untreated symptomatic multiple myeloma in patients not suitable for high dose chemotherapy (as part of combination therapy with a… | Jul 2009 | Recommended with restriction | unclear |
| Thalidomide Treatment of patients newly diagnosed with multiple myeloma who are ineligible for treatment with high dose chemotherapy or a stem cell transplant; and… | Mar 2009 | Recommended with restriction | no section in document |
| doxorubicin hydrochloride, pegylated liposomal treatment of refractory multiple myeloma in combination with bortezomib | Jul 2008 | Not recommended | no section in document |
| lenalidomide Treatment of patients with relapsed/refractory multiple myeloma for whom thalidomide therapy has failed or in whom there is severe intolerance/toxicity to… | Nov 2008 | Recommended with restriction | no section in document |
| bortezomib treatment of multiple myeloma patients who have failed specified other therapy, are ineligible for a primary stem cell transplant and meet certain criteria | Jul 2007 | Recommended with restriction | no section in document |
| bortezomib Treatment of multiple myeloma in patients who have received at least one prior therapy and have progressive disease, with good performance status following… | Jul 2007 | Recommended with restriction | no section in document |
| bortezomib initial and continuing treatment of multiple myeloma patients who have failed specified other therapy and meet certain criteria | Mar 2006 | Not recommended | no section in document |
| bortezomib Initial and continuing treatment of multiple myeloma patients who have failed specified other therapy, specifically those with WHO performance status 0-2 who… | Mar 2006 | Not recommended | no section in document |
| bortezomib treatment of multiple myeloma in patients who have progressive disease with a WHO performance status of 2 or less, who have received at least one prior therapy… | Nov 2006 | Not recommended | no section in document |
| bortezomib Treatment of multiple myeloma in patients with progressive disease who have received at least one prior therapy and have already undergone or are ineligible… | Nov 2006 | Not recommended | no section in document |
Who spoke
Myeloma Australia · Leukaemia Foundation · Rare Cancers Australia · Leukemia Foundation · Scientific Group · Haematology Society · South East Myeloma Support Group · National Institute
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 42 of 54 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.